[Chemotherapy of gastric cancer].
At present curative resection is the only radical treatment for gastric cancer, although recently developed combination chemotherapy shows increased activity in treating locally advanced and metastatic disease. Among several combination regimens, those based on biochemical modulation, such as sequential methotrexate/5-fluorouracil or low-dose CDDP/5-fluorouracil, are thought to provide increased efficacy with decreasing adverse reactions in unresectable gastric cancer. Therefore, a prospective randomized clinical trial comparing the prognosis of patients receiving adjuvant multi-agent chemotherapy with those treated only surgically should be pursued for estimation of the clinical benefit of these agents.
Konishi
T
T
Department of Surgery, Showa General Hospital, Tokyo, Japan.
Teruya
M
M
Kawahara
M
M
Itoh
A
A
Asakura
R
R
Araki
S
S
Hojo
K
K
Nouchi
T
T
Takeda
Y
Y
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077146:Irinotecan; D008727:Methotrexate / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000972:Antineoplastic Agents, Phytogenic; D007155:Immunologic Factors; D005047:Etoposide; D000077146:Irinotecan; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil; D002166:Camptothecin; D008727:Methotrexate